AF
GTBP icon

Amalgamated Financial’s GT Biopharma GTBP Stock Holding History

Amalgamated Financial’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$9K Buy
+99
New +$8.73K ﹤0.01% 2910

Other funds holding GTBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Amalgamated Financial's GTBP Position: Q1 2022 in Review

Amalgamated Financial opened a new position in GT Biopharma (GTBP) in Q1 2022: 99 shares worth $9K. The stake represents ﹤0.01% of the portfolio and ranks #2910 among its holdings.

57 funds tracked by Wall St. Rank hold GTBP as of Q1 2022.

  • Amalgamated Financial held 99 shares of GT Biopharma worth $9K as of Q1 2022.
  • GT Biopharma was a new Amalgamated Financial position in Q1 2022.
  • GT Biopharma made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2910 holding.
  • 57 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.